# Sex-based clinical and immunological differences across lupus erythematosus subtypes: a cross-sectional multicentre study from China

**Authors:** Yu Pan, Hui Jin, Shihang Zhou, Zhang Ying, Leilei Bai, Qianjin Lu

PMC · DOI: 10.1136/lupus-2025-001783 · Lupus Science & Medicine · 2026-02-23

## TL;DR

This study explores how sex influences clinical and immune features in different types of lupus erythematosus in a Chinese population.

## Contribution

The study reveals sex-specific patterns in clinical and immunological features across lupus subtypes in a large Chinese cohort.

## Key findings

- Female predominance was observed in all lupus subtypes, with notable differences in lesion types and autoantibody profiles.
- Females showed higher frequencies of arthritis, non-scarring alopecia, and specific autoantibodies compared to males.
- Sex differences in systemic disease tendencies vary by lupus subtype, with females more prone to systemic involvement in some subtypes.

## Abstract

To investigate sex-related differences in clinical and immunological features across lupus erythematosus (LE) subtypes.

This cross-sectional analysis, based on the Lupus Erythematosus Multicenter Case–Control Study in Chinese populations (ChiCTR2100048939), included patients with SLE and major cutaneous LE (CLE) subtypes. Sex-specific comparisons were performed using R V.4.4.2.

In 2097 patients (1865 SLE, 1648 CLE), female predominance was observed in all subtypes, with female-to-male ratios ranging from 11.3:1 (acute CLE, ACLE) to 2.1:1 (isolated CLE, iCLE). Except for ACLE, females had earlier or similar onset than males in all other subtypes. ACLE lesions were most common in females (67%). In male patients with LE, the proportion of discoid LE (DLE) lesions was higher than female patients (31% vs 12%). Compared with males, females exhibited higher frequencies of arthritis in SLE, ACLE, DLE and chilblain LE (CHLE). In DLE, renal involvement, haematological abnormalities and serositis were more frequently observed in females. In subacute CLE (SCLE), haematological abnormalities were significantly more common in females. Additionally, non-scarring alopecia was more common in females than in males. Females had higher autoantibody positivity in iCLE and chronic CLE, with significant differences in anti-double-stranded DNA, anti-Smith, anti-U1-nuclear ribonucleoprotein and anti-ribosomal P antibodies.

Across the subtypes, several clinical manifestations show a consistent sex distribution: ACLE lesions, arthritis, non-scarring alopecia, Raynaud’s phenomenon and autoantibodies occur more frequently in women with LE, whereas the proportions of DLE and SCLE lesions are higher in men with LE. In addition, certain features exhibit subtype-specific sex differences: among patients with SCLE, DLE and CHLE, women show a greater propensity for systemic involvement, whereas in those with SLE and ACLE, men demonstrate a higher tendency toward systemic disease.

ChiCTR2100048939.

## Linked entities

- **Diseases:** lupus erythematosus (MONDO:0004670), SLE (MONDO:0007915)

## Full-text entities

- **Genes:** TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, SNRNP70 (small nuclear ribonucleoprotein U1 subunit 70) [NCBI Gene 6625] {aka RNPU1Z, RPU1, SNRP70, Snp1, U1-70K, U170K}, RO60 (Ro60, Y RNA binding protein) [NCBI Gene 6738] {aka RORNP, SSA2, TROVE2}, SSB (small RNA binding exonuclease protection factor La) [NCBI Gene 6741] {aka LARP3, La, La/SSB, SSB/La}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}
- **Diseases:** H (MESH:D000848), malar rash (MESH:C000721270), Raynaud phenomenon (MESH:D011928), serositis (MESH:D012700), renal damage (MESH:D007674), purpura (MESH:D011693), renal and haematological involvement (MESH:C565423), multiorgan involvement (MESH:C564676), K (MESH:D014813), neuropsychiatric involvement (MESH:C000631768), L (MESH:D007926), J (MESH:C563874), haematological abnormalities (MESH:D006402), Mucocutaneous symptoms (MESH:D012816), arthritis (MESH:D001168), lupus erythematosus profundus (MESH:D015435), systemic disease (MESH:D034721), Lupus Erythematosus (MESH:D008180), fever (MESH:D005334), Cutaneous Lupus Erythematosus (MESH:D008178), specific (MESH:D000080888), neurological symptoms (MESH:D009461), I (MESH:D006969), non-scarring alopecia (MESH:D002921), lupus-specific skin manifestations (MESH:D012877), multiorgan autoimmune disorder (MESH:D001327), ACLE lesions (MESH:D009059), alopecia (MESH:D000505), cutaneous (MESH:D018366), CCLE (MESH:D008179), CHLE (MESH:C535924), neurological involvement (MESH:C538190), skin lesions (MESH:D012871), physical disabilities (MESH:D059445), visual or auditory impairment (MESH:D014786), oral ulcers (MESH:D019226), disease (MESH:D004194), vasculitis (MESH:D014657), inflammatory (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12931554/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12931554/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12931554/full.md

---
Source: https://tomesphere.com/paper/PMC12931554